Theratechnologies Inc. (THTX)
USD 1.98
(48.88%)
USD 1.98
(48.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 24.87 Million USD | -41.96% |
| 2022 | 42.85 Million USD | 17.91% |
| 2021 | 36.34 Million USD | -14.77% |
| 2020 | 42.64 Million USD | 93.14% |
| 2019 | 22.08 Million USD | 129.52% |
| 2018 | 9.62 Million USD | 66.1% |
| 2017 | 5.79 Million USD | -37.73% |
| 2016 | 9.3 Million USD | 694.2% |
| 2015 | 1.17 Million USD | 292.56% |
| 2014 | -608.2 Thousand USD | 33.39% |
| 2013 | -913.02 Thousand USD | 40.01% |
| 2012 | -1.52 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 26.86 Million USD | 8.01% |
| 2024 Q3 | 22.45 Million USD | -17.78% |
| 2024 Q2 | 28.15 Million USD | 4.79% |
| 2023 Q3 | 43.27 Million USD | -12.96% |
| 2023 Q1 | 45.96 Million USD | 7.25% |
| 2023 Q4 | 24.87 Million USD | -42.53% |
| 2023 FY | 24.87 Million USD | -41.96% |
| 2023 Q2 | 49.71 Million USD | 8.17% |
| 2022 Q2 | 44.25 Million USD | 3.48% |
| 2022 Q4 | 42.85 Million USD | -0.38% |
| 2022 Q3 | 43.01 Million USD | -2.79% |
| 2022 FY | 42.85 Million USD | 17.91% |
| 2022 Q1 | 42.76 Million USD | 23.23% |
| 2021 FY | 36.34 Million USD | -14.77% |
| 2021 Q3 | 28.96 Million USD | 26.84% |
| 2021 Q1 | 11.4 Million USD | -73.25% |
| 2021 Q4 | 34.7 Million USD | 19.8% |
| 2021 Q2 | 22.83 Million USD | 100.18% |
| 2020 Q1 | 30.62 Million USD | 38.7% |
| 2020 FY | 42.64 Million USD | 93.14% |
| 2020 Q2 | 33.08 Million USD | 8.04% |
| 2020 Q3 | 37.8 Million USD | 14.25% |
| 2020 Q4 | 42.64 Million USD | 12.81% |
| 2019 Q3 | 19.31 Million USD | -2.84% |
| 2019 Q1 | 9.39 Million USD | -8.21% |
| 2019 Q2 | 19.87 Million USD | 111.57% |
| 2019 FY | 22.08 Million USD | 129.52% |
| 2019 Q4 | 22.08 Million USD | 14.32% |
| 2018 Q2 | -2.33 Million USD | -72.3% |
| 2018 FY | 9.62 Million USD | 66.1% |
| 2018 Q1 | -1.35 Million USD | 0.67% |
| 2018 Q4 | 10.23 Million USD | -31.14% |
| 2018 Q3 | 14.86 Million USD | 736.7% |
| 2017 Q4 | -1.36 Million USD | -32.26% |
| 2017 FY | 5.79 Million USD | -37.73% |
| 2017 Q3 | -1.03 Million USD | 65.79% |
| 2017 Q2 | -3.01 Million USD | 44.84% |
| 2017 Q1 | -5.46 Million USD | -593.32% |
| 2016 Q2 | -3.61 Million USD | 56.81% |
| 2016 FY | 9.3 Million USD | 694.2% |
| 2016 Q4 | -788.54 Thousand USD | -223.19% |
| 2016 Q3 | -243.98 Thousand USD | 93.24% |
| 2016 Q1 | -8.36 Million USD | 27.39% |
| 2015 Q3 | -11.44 Million USD | -213.0% |
| 2015 FY | 1.17 Million USD | 292.56% |
| 2015 Q2 | -3.65 Million USD | -122.89% |
| 2015 Q4 | -11.51 Million USD | -0.6% |
| 2015 Q1 | 15.97 Million USD | 2727.12% |
| 2014 Q3 | -2.32 Million USD | -714.01% |
| 2014 Q2 | -285.48 Thousand USD | -33.5% |
| 2014 Q1 | -213.84 Thousand USD | 76.58% |
| 2014 FY | -608.2 Thousand USD | 33.39% |
| 2014 Q4 | -608.2 Thousand USD | 73.83% |
| 2013 Q2 | -389.63 Thousand USD | -407.17% |
| 2013 FY | -913.02 Thousand USD | 40.01% |
| 2013 Q4 | -913.02 Thousand USD | 40.69% |
| 2013 Q3 | -1.53 Million USD | -295.11% |
| 2013 Q1 | -76.82 Thousand USD | 94.95% |
| 2012 FY | -1.52 Million USD | 0.0% |
| 2012 Q4 | -1.52 Million USD | 40.59% |
| 2012 Q2 | -1.01 Million USD | -1495.8% |
| 2012 Q1 | -63.36 Thousand USD | 97.44% |
| 2012 Q3 | -2.56 Million USD | -153.35% |
| 2011 Q1 | -543.96 Thousand USD | 97.92% |
| 2011 Q4 | -2.47 Million USD | -380.41% |
| 2011 Q3 | -515.85 Thousand USD | 50.11% |
| 2011 Q2 | -1.03 Million USD | -90.07% |
| 2010 Q4 | -26.13 Million USD | -1069.52% |
| 2010 Q1 | -3.17 Million USD | -120.73% |
| 2010 Q2 | -3.31 Million USD | -4.55% |
| 2010 Q3 | -2.23 Million USD | 32.57% |
| 2009 Q4 | -1.43 Million USD | 87.64% |
| 2009 Q1 | -5.42 Million USD | -4968.41% |
| 2009 Q2 | -3.51 Million USD | 35.2% |
| 2009 Q3 | -11.61 Million USD | -230.31% |
| 2008 Q3 | -9.05 Million USD | -12.75% |
| 2008 Q1 | -17.74 Million USD | -588.52% |
| 2008 Q2 | -8.02 Million USD | 54.75% |
| 2008 Q4 | -107.09 Thousand USD | 98.82% |
| 2007 Q2 | -11.82 Million USD | 74.84% |
| 2007 Q3 | -6.19 Million USD | 47.63% |
| 2007 Q1 | -47 Million USD | -335266.71% |
| 2007 Q4 | -2.57 Million USD | 58.4% |
| 2006 Q2 | -1.54 Million USD | -2417.14% |
| 2006 Q1 | -61.51 Thousand USD | 93.39% |
| 2006 Q3 | -1.39 Million USD | 9.62% |
| 2006 Q4 | -14.01 Thousand USD | 99.0% |
| 2005 Q3 | -4.01 Million USD | 33.7% |
| 2005 Q4 | -930.69 Thousand USD | 76.82% |
| 2005 Q2 | -6.05 Million USD | -34.58% |
| 2005 Q1 | -4.49 Million USD | -1125.4% |
| 2004 Q1 | -15.94 Million USD | -38942.15% |
| 2004 Q2 | -2.63 Million USD | 83.48% |
| 2004 Q3 | -345.85 Thousand USD | 86.87% |
| 2004 Q4 | -367.19 Thousand USD | -6.17% |
| 2003 Q2 | -4.35 Million USD | -30.75% |
| 2003 Q3 | -1.9 Million USD | 56.36% |
| 2003 Q1 | -3.33 Million USD | -2560.69% |
| 2003 Q4 | -40.83 Thousand USD | 97.85% |
| 2002 Q4 | -125.24 Thousand USD | 98.69% |
| 2002 Q1 | -13.06 Million USD | -741.73% |
| 2002 Q2 | -7.1 Million USD | 45.6% |
| 2002 Q3 | -9.56 Million USD | -34.66% |
| 2001 Q1 | -1.17 Million USD | -33.02% |
| 2001 Q4 | -1.55 Million USD | 92.44% |
| 2001 Q3 | -20.51 Million USD | -187.96% |
| 2001 Q2 | -7.12 Million USD | -506.89% |
| 2000 Q1 | -1.92 Million USD | -610.36% |
| 2000 Q4 | -882.58 Thousand USD | 92.49% |
| 2000 Q3 | -11.75 Million USD | 3.2% |
| 2000 Q2 | -12.14 Million USD | -529.49% |
| 1999 Q4 | -271.63 Thousand USD | 98.3% |
| 1999 Q1 | -9.28 Million USD | 9.2% |
| 1999 Q3 | -15.99 Million USD | -22.17% |
| 1999 Q2 | -13.08 Million USD | -41.04% |
| 1998 Q2 | -11.19 Million USD | -96.62% |
| 1998 Q3 | -10.12 Million USD | 9.53% |
| 1998 Q4 | -10.22 Million USD | -0.96% |
| 1998 Q1 | -5.69 Million USD | 18.19% |
| 1997 Q4 | -6.95 Million USD | 16.69% |
| 1997 Q1 | -9.64 Million USD | 0.0% |
| 1997 Q3 | -8.35 Million USD | -4.63% |
| 1997 Q2 | -7.98 Million USD | 17.25% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -1250.419% |
| Alpha Teknova, Inc. | 1.97 Million USD | -1159.929% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 73.6% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 66.817% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 94.287% |
| Cosmos Health Inc. | 8.59 Million USD | -189.509% |
| Journey Medical Corporation | -9.7 Million USD | 356.164% |
| Embecta Corp. | 1.31 Billion USD | 98.104% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 94.578% |
| Dynavax Technologies Corporation | 106.63 Million USD | 76.677% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 119.01% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 94.253% |
| PainReform Ltd. | -7.95 Million USD | 412.843% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 259.076% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 259.076% |
| SCYNEXIS, Inc. | -19.35 Million USD | 228.532% |
| Safety Shot Inc | -2.28 Million USD | 1188.744% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 363.751% |
| Procaps Group, S.A. | 242.93 Million USD | 89.762% |
| Harrow Health, Inc. | 116.41 Million USD | 78.636% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 1086.944% |
| Biofrontera Inc. | 4.05 Million USD | -513.19% |
| DURECT Corporation | -7.65 Million USD | 424.941% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 174.182% |
| Cronos Group Inc. | -663.32 Million USD | 103.749% |
| OptiNose, Inc. | 58.06 Million USD | 57.167% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 96.01% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 270.677% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 579.577% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -65.663% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 491.075% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -23174.595% |
| Radius Health, Inc. | 359.28 Million USD | 93.078% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -12511.493% |
| ProPhase Labs, Inc. | 19.23 Million USD | -29.328% |
| Phibro Animal Health Corporation | 454.84 Million USD | 94.532% |
| Procaps Group S.A. | 242.93 Million USD | 89.762% |
| Alvotech | 1.06 Billion USD | 97.663% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -576.21% |
| Viatris Inc. | 17.13 Billion USD | 99.855% |
| Rockwell Medical, Inc. | 4.45 Million USD | -458.146% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 609.965% |
| SIGA Technologies, Inc. | -148.68 Million USD | 116.728% |
| Tilray Brands, Inc. | 158.97 Million USD | 84.356% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 79.597% |
| Shineco, Inc. | 29.29 Million USD | 15.088% |
| PetIQ, Inc. | 351.93 Million USD | 92.933% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 957.199% |
| Incannex Healthcare Limited | -5.48 Million USD | 553.437% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 85.972% |
| Alimera Sciences, Inc. | 55.3 Million USD | 55.033% |
| Silver Spike Investment Corp. | -32.61 Million USD | 176.264% |
| Assertio Holdings, Inc. | -32.52 Million USD | 176.458% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 1770.628% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 591.484% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 616.639% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 402.807% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -489.779% |
| Hempacco Co., Inc. | 13.61 Million USD | -82.678% |
| Talphera, Inc. | -5.72 Million USD | 534.732% |
| Alvotech | 1.06 Billion USD | 97.663% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -248.09% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 125.717% |
| Currenc Group, Inc. | -16.57 Million USD | 250.068% |
| Kamada Ltd. | -46.43 Million USD | 153.565% |
| Indivior PLC | -33.95 Million USD | 173.253% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -9444.697% |
| Flora Growth Corp. | -713 Thousand USD | 3588.219% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 402.807% |
| Evolus, Inc. | 63.7 Million USD | 60.961% |
| HUTCHMED (China) Limited | -197.45 Million USD | 112.596% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 94.809% |
| Akanda Corp. | 3.9 Million USD | -536.915% |